Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

Warner-Lambert pleads guilty to GMP violations, will pay $10 mil. fine.

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

WARNER-LAMBERT PLEADS GUILTY TO GMP VIOLATIONS, WILL PAY $10 MIL. FINE for "fraudulently failing to notify the FDA about persistent drug stability problems," the Maryland U.S. Attorney's Office announced Nov. 28. The company pleaded guilty to the felony offense before Judge Deborah Chasanow in Greenbelt, Md. federal court.

You may also be interested in...



Schering GMP Criminal Investigation Continues After Consent Decree

Schering-Plough faces a potential criminal case regarding GMP violations after finalizing a consent agreement with FDA May 17

Schering GMP Criminal Investigation Continues After Consent Decree

Schering-Plough faces a potential criminal case regarding GMP violations after finalizing a consent agreement with FDA May 17

Schering GMP Criminal Investigation Continues After Consent Decree

Schering-Plough faces a potential criminal case regarding GMP violations after finalizing a consent agreement with FDA May 17

Table

View full table

Topics

Tags:
Consumer OTC Drugs
Latest Headlines

Changes To EU Pharma Reform: More Questions Than Answers?

Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Khan Says

See All
UsernamePublicRestriction

Register

PS084565

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By